COMPANY
Otsuka
Raises and deals from press releases
- Deal Deal · $700M · announced Jun 12, 2026 Company release ↗
Source quote
- Jun 12, 2026 · Company release ↗
“Under the terms of the agreement, Otsuka paid $700 million to Transcend shareholders at closing, with up to $525 million in additional contingent consideration based on future sales related to assets in development.”
- Jun 12, 2026 · Company release ↗
Timeline
- Trial start Phase 3: A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia source ↗
- Trial start —: LUPKYNIS Drug-use Results Survey source ↗
- Trial start Phase 3: A Long-term Trial of EB-1020 in Pediatric Patients With ADHD source ↗
- Trial start Phase 2/Phase 3: A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD source ↗
- Trial start Phase 3: A Long-term Trial of EB-1020 in Adult Patients With ADHD source ↗
- Trial start Phase 2/Phase 3: Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients source ↗
- Trial start —: REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Du source ↗
- Trial start Phase 1: Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia source ↗
- Trial start —: Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure. source ↗
- Trial start Phase 3: A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia source ↗
- Trial start Phase 3: A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia source ↗
- Trial start Phase 2: A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) source ↗
- Trial start Phase 3: Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia source ↗
- Trial start Phase 3: A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia source ↗
- Trial start Phase 3: A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis source ↗
- Trial start —: Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use source ↗
- Trial start Phase 1: A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia source ↗
- Trial start —: Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP) source ↗
- Trial start —: Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH source ↗
- Trial start Phase 2: A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia source ↗
- Trial start Phase 1/Phase 2: Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma source ↗
- Trial start I: A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma source ↗
- Trial start Phase 3: A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients source ↗
- Trial start 3: A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis source ↗
- Trial start 3: A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis source ↗
Upcoming milestones
- 2026-12 (ESTIMATED) · 3 · A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis · NCT07173478
- 2027-02 (ESTIMATED) · 3 · A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis · NCT07184645
- 2027-08 (ESTIMATED) · Phase 3 · A Long-term Trial of EB-1020 in Pediatric Patients With ADHD · NCT07087327
- 2027-08 (ESTIMATED) · Phase 2/Phase 3 · A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD · NCT07086313
- 2027-09 (ESTIMATED) · Phase 3 · Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia · NCT05325645
- Sep 30, 2027 (ESTIMATED) · · REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due t · NCT06875986
- 2027-12 (ESTIMATED) · Phase 3 · A Long-term Trial of EB-1020 in Adult Patients With ADHD · NCT06926829
- 2027-12 (ESTIMATED) · Phase 2/Phase 3 · Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients · NCT06931080
Clinical trials (lead sponsor) Showing 50 of 143
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05325645 | Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia | Phase 3 | Recruiting | Jul 21, 2022 | 2027-09 (estimated) |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | Phase 1/Phase 2 | Terminated | Feb 18, 2021 | Apr 9, 2025 (actual) |
| NCT05326347 | A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia | Phase 3 | Completed | May 31, 2022 | Aug 26, 2025 (actual) |
| NCT05712746 | Samtasu Post-marketing General Drug Use-results Survey in Patients With Volume Overload in Heart Failure. | Not listed | Active, not recruiting | Mar 3, 2023 | May 7, 2026 (actual) |
| NCT04790175 | Samsca Post-marketing General Drug Use-results Survey in Patients With Hyponatremia in SIADH | Not listed | Active, not recruiting | Mar 29, 2021 | Jan 19, 2026 (actual) |
| NCT05342493 | Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use | Not listed | Recruiting | Apr 20, 2022 | Sep 30, 2026 (estimated) |
| NCT04049825 | A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL | 1 | Completed | Nov 22, 2019 | Mar 25, 2025 (actual) |
| NCT04362007 | A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma | I | Terminated | Jul 14, 2020 | Nov 30, 2024 (actual) |
| NCT05687071 | A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Phase 3 | Completed | Feb 27, 2023 | Oct 5, 2024 (actual) |
| NCT06036108 | Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia | Phase 1 | Completed | Oct 3, 2023 | Mar 18, 2025 (actual) |
| NCT07225712 | A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia | Phase 3 | Recruiting | Dec 22, 2025 | 2028-03 (estimated) |
| NCT07087327 | A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | Phase 3 | Recruiting | Sep 16, 2025 | 2027-08 (estimated) |
| NCT07086313 | A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | Phase 2/Phase 3 | Recruiting | Sep 3, 2025 | 2027-08 (estimated) |
| NCT02847624 | Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD | Not listed | Completed | Mar 24, 2014 | Sep 20, 2022 (actual) |
| NCT05615363 | A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF]) | Phase 2 | Completed | Jan 10, 2023 | Oct 21, 2024 (actual) |
| NCT07184645 | A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | 3 | Not yet recruiting | 2025-09 | 2027-02 (estimated) |
| NCT07053891 | LUPKYNIS Drug-use Results Survey | Not listed | Recruiting | Sep 17, 2025 | Jun 30, 2031 (estimated) |
| NCT07173478 | A Phase 3 Trial to Demonstrate the Superiority of 1% OPA-15406 Foam to the Vehicle in Adult Patients With Atopic Dermatitis | 3 | Not yet recruiting | 2025-10 | 2026-12 (estimated) |
| NCT06926829 | A Long-term Trial of EB-1020 in Adult Patients With ADHD | Phase 3 | Recruiting | Jun 25, 2025 | 2027-12 (estimated) |
| NCT06931080 | Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients | Phase 2/Phase 3 | Recruiting | Apr 30, 2025 | 2027-12 (estimated) |
| NCT06875986 | REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease) | Not listed | Recruiting | Apr 17, 2025 | Sep 30, 2027 (estimated) |
| NCT05372653 | A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis | Phase 3 | Completed | May 23, 2022 | Dec 29, 2022 (actual) |
| NCT04107051 | Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence | Not listed | Completed | Oct 1, 2019 | Feb 7, 2023 (actual) |
| NCT04812379 | Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP) | Not listed | Completed | Apr 7, 2021 | Sep 13, 2023 (actual) |
| NCT03906695 | Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes | 1 | Active, not recruiting | Mar 15, 2019 | Jan 31, 2026 (estimated) |
| NCT05683340 | A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia | Phase 3 | Completed | Feb 13, 2023 | Feb 20, 2024 (actual) |
| NCT03620981 | Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type | Phase 2/Phase 3 | Completed | Aug 20, 2018 | Apr 21, 2023 (actual) |
| NCT03724942 | Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type | Phase 3 | Completed | Nov 9, 2018 | Dec 2, 2021 (actual) |
| NCT04244253 | A Phase 2 Trial of OPC-64005 for Major Depressive Disorder | 2 | Completed | Mar 3, 2020 | Feb 8, 2022 (actual) |
| NCT03255226 | Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload | Phase 3 | Completed | Mar 7, 2018 | Jul 11, 2021 (actual) |
| NCT03697603 | A Study of Brexpiprazole in Patients With Major Depressive Disorder | Phase 2/Phase 3 | Completed | Jul 30, 2018 | Jun 6, 2022 (actual) |
| NCT01617460 | A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder | Phase 3 | Completed | 2012-09 | 2016-10 (actual) |
| NCT04118127 | A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses | Phase 1 | Completed | Oct 17, 2019 | Feb 16, 2021 (actual) |
| NCT04784442 | A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia | Phase 2 | Completed | Mar 24, 2021 | Apr 18, 2022 (actual) |
| NCT03737474 | A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder | Phase 3 | Completed | Oct 4, 2018 | Mar 17, 2021 (actual) |
| NCT03303105 | Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine | Phase 3 | Completed | Dec 7, 2017 | Jun 16, 2020 (actual) |
| NCT05119894 | A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia | Phase 1 | Withdrawn | Nov 22, 2021 | Dec 6, 2021 (actual) |
| NCT03961529 | Long-term Trial of OPA-15406 Ointment in Adult and Pediatric Patients With Atopic Dermatitis | Phase 3 | Completed | May 14, 2019 | Nov 11, 2020 (actual) |
| NCT04355117 | A Safety Evaluation Trial of TEV-48125 Self-administered in Migraine Patients | Phase 3 | Completed | Jun 17, 2020 | Nov 11, 2020 (actual) |
| NCT02085460 | A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer | 2 | Completed | 2014-03 | 2015-08 (actual) |
| NCT02554721 | Pharmacodynamic Study of Cilostazol in Healthy Volunteers | Phase 1 | Completed | 2015-08 | Mar 30, 2018 (actual) |
| NCT04182958 | A Phase I, Open-Label Trial to Assess the Absorption, Metabolism, and Excretion of (14C)-OPC-61815 in Healthy Male Japanese Subjects | I | Completed | Nov 25, 2019 | Dec 19, 2019 (actual) |
| NCT03179787 | Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism | Not listed | Completed | Apr 1, 2017 | Mar 17, 2020 (actual) |
| NCT03962101 | Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake | Phase 3 | Completed | Jun 17, 2019 | Jun 30, 2020 (actual) |
| NCT03772041 | Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure | Phase 3 | Completed | Jan 16, 2019 | Jul 21, 2020 (actual) |
| NCT03303092 | Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine | Phase 2/Phase 3 | Completed | Dec 19, 2017 | Nov 22, 2019 (actual) |
| NCT03254108 | Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure | Not phased (device or behavioral study) | Completed | Nov 6, 2017 | Apr 14, 2018 (actual) |
| NCT00463151 | An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis | Phase 2 | Completed | 2007-06 | 2008-08 (actual) |
| NCT03902574 | Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2mg | Phase 1 | Completed | Mar 27, 2019 | Jun 18, 2019 (actual) |
| NCT01471093 | Safety Study of OPC-12759 Ophthalmic Solution | Phase 1 | Completed | 2011-11 | 2011-12 (actual) |